Skip to content

Clinical trials

Brain Neoplasms trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Brain Neoplasms Phase: Not applicable Clear all

505 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20022
20032
20045
20054
20066
20077
20086
20098
201011
201111
201221
201319
201420
201522
201625
201737
201824
201927
202026
202136
202235
202340
202425
202540
202637

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed178
Recruiting118
Unknown status64
Terminated42
Active, not recruiting34
Not yet recruiting31
Withdrawn24
Suspended8
Enrolling by invitation6

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Memorial Sloan Kettering Cancer Center14
M.D. Anderson Cancer Center13
Mayo Clinic11
University Health Network, Toronto11
Massachusetts General Hospital10
Virginia Commonwealth University9
Duke University8
Jonsson Comprehensive Cancer Center7
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins6
Sklifosovsky Institute of Emergency Care6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Brain Neoplasms505
Glioma63
Glioblastoma58
Neoplasms26
Breast Neoplasms25
Meningioma24
Neoplasm Metastasis21
Lung Neoplasms19
Head and Neck Neoplasms15
Astrocytoma14

Trials

Showing 1 to 25 of 505. Each trial links to its page on Pharma Observatory.

405 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.